eHealth, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by eHealth, Inc. on March 7, 2017. The filing discloses the approval of a new Executive Bonus Plan for the fiscal year ending December 31, 2017, by the Company's Compensation Committee.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on executive compensation structures and performance targets for the upcoming fiscal year.
Material Changes and Compensation Details
The Compensation Committee approved the following changes to executive compensation for fiscal year 2017:
- Performance Metrics: Payouts are determined 100% by company performance. Key metrics include Revenue and Adjusted EBITDA. Adjusted EBITDA is defined as GAAP net income (loss) plus stock-based compensation, depreciation and amortization, other expense, net, provision for income taxes, and restructuring charges.
- Executive Bonus Targets (Cash):
- David K. Francis: Target $240,000; Maximum $360,000. Goals: 60% Revenue, 40% Adjusted EBITDA.
- Robert S. Hurley: Target $195,000; Maximum $292,500. Goals: 25% Revenue/EBITDA, 75% Medicare business goals.
- Tom G. Tsao: Target $228,000; Maximum $336,528. Goals: 25% Revenue/EBITDA, 75% Individual/Family/Small Business insurance goals.
- CEO Compensation Change: CEO Scott Flanders will receive a performance-based stock option in lieu of a cash bonus. The option value is capped at $900,000 (representing 150% of a hypothetical target cash bonus). Vesting is contingent on achieving Revenue (60%) and Adjusted EBITDA (40%) goals. The option grant date is March 31, 2017.
- Payout Rules: No payout occurs if goals are achieved below a threshold (75%-95% of target). Maximum payout is 150% of the target for overachievement.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or general outlook commentary. The primary risk disclosed relates to the forfeiture of the CEO's stock option if specific revenue and Adjusted EBITDA performance goals are not met.
Key Facts for Investor Verification
- Verify the specific revenue and Adjusted EBITDA targets set for 2017 to assess the difficulty of achieving the executive bonuses.
- Monitor the March 31, 2017 stock price to determine the exact number of shares granted to CEO Scott Flanders.
- Review future filings to confirm whether the performance thresholds for the Medicare and individual/family business segments were met.
- Note that the filing defines Adjusted EBITDA with specific add-backs; investors should reconcile this with the company's standard non-GAAP reporting.